Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biogen Idec beats Street

BIIB reported first quarter EPS of $0.40, beating the Street estimate by $0.06.

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE